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Abstract 
Review on MYO1A, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: BBMI, DFNA48, MIHC, MYHL 
HGNC (Hugo): MYO1A 
Location: 12q13.3 
 
Note 
Orientation: minus strand. 
DNA/RNA 
Description 
There are several transcripts described for MYO1A. 
The two transcripts better characterized contain 28 
and 29 exons spanning over 21 kb and both code 
for an identical protein of 1043 amino acids. 
 
Figure 1. Diagram of DNA/RNA. 
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Figure 2. Protein structure of MYO1A. 
 
 
 
Protein 
Description 
The protein encoded by the MYOSIN-IA gene 
belongs to the myosin superfamily.  
Like all myosin-1 isoforms, MYO1A contain these 
three core domains (figure 2): an N-terminal motor 
domain that coordinates ATP hydrolysis with actin 
binding and force generation; a central neck region 
made up of varying numbers of IQ motifs, which 
bind calmodulin or calmodulin-like proteins; and a 
tail region, which includes a highly basic C-
terminal tail homology 1 (TH1) domain that is 
responsible for membrane binding (Coluccio and 
Bretscher, 1990; Krendel and Mooseker, 2005; 
McConnell and Tyska, 2010; Nambiar et al., 2010). 
Expression 
Myo1a is highly expressed in the enterocytes that 
line the mucosa of the small intestine (Matsudaira 
and Burgess, 1979; Skowron and Mooseker, 1999). 
Expression of MYO1A has also been observed at 
relatively high levels in gastric epithelium when 
compared to other organs such as endometrium, 
myometrium, ovary and prostate (figure 3).  
In tumor samples, MYO1A mRNA expression in 
human gastric adenocarcinomas is comparable to 
intestinal adenocarcinomas, and significantly higher 
than in other tumor types (Mazzolini et al., 2013) 
(figure 4).  
Myo1a transcripts are also present in rodent inner 
ear at low level (Dumont et al., 2002). 
Localisation 
Myo1a localizes to the cellular membrane through 
to the C-terminal tail domain.  
In the enterocytes that line the mucosa of the small  
intestine, MYO1A localizes to the apical brush 
border membrane (Matsudaira and Burgess, 1979; 
Collins and Borysenko, 1984; Skowron and 
Mooseker, 1999) (figure 5). 
Function 
Myosin Ia (MYO1A) is a major component of the 
cytoskeleton that underlies and supports the apical  
 
 
brush border of the enterocytes.  
MYO1A forms a spiral array of bridges that links 
the microvillar actin core to the membrane 
(Chantret et al., 1988; West et al., 1988; Beaulieu et 
al., 1990).  
Here, Myosin-1a plays a critical role in maintaining 
the brush border composition, structure, and 
regulating the microvillar membrane tension (Tyska 
et al., 2005; Nambiar et al., 2009), Myo1a also 
plays a role in powering the release of vesicles from 
the tips of the microvilli (McConnell et al., 2009). 
 
 
Figure 3. Relative MYO1A mRNA levels in human normal 
tissues. MYO1A mRNA levels in human normal and tumor 
samples were obtained from a collection of 667 normal 
human samples from different tissues (Gene Expression 
Omnibus: GSE7307) and 10000 normal and tumor samples 
from GeneSapiens.org (Kilpinen et al., 2008). 
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Figure 4. Relative MYO1A mRNA levels in human tumors of different origin. Box-whisker plot of the gene's expression in cancer 
tissues. The bottom of the box is the 25th percentile of the data, the top of the box is the 75th percentile, and the vertical red line 
is the median. The whiskers extend to 1.5 times the interquartile range from the edges of the box, and any data points beyond 
this are considered outliers, marked by hollow circles. Filled grey bars are gastrointestinal carcinomas. 
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Figure 5. MYO1A localizes to the apical membrane of intestinal epithelial cells. MYO1A-GFP was transfected into the colon 
cancer cell line Caco-2. The image was taken by confocal microscopy and represents an orthogonal stuck of a monolayer of 
cells. (A) Actin staining with rhodamine-phalloidin shows the apical and baso-lateral membtanes of the cells. (B) EGFP-MYO1A 
localizing in the apical membrane. (C) Overlay (modified from Mazzolini et al., 2012). 
 
 
Mutations 
Germinal 
The following germinal mutations have been 
reported in eight unrelated patients coming from 
central and southern Italy and affected by 
sensorineural bilateral hearing loss of variable 
degree: one nonsense mutation, one trinucleotide 
insertion leading to an additional amino acid, and 
six missense mutations (Donaudy et al., 2003) 
(table 1). 
Somatic 
Mazzolini et al. reported frequent frame-shift 
somatic mutations in colorectal and gastric cancer. 
These mutations were found with the following 
frequencies: 44,4% (16 of 36) in microsatellite- 
instable colorectal cancer cell lines; 31,3% (42 of 
134) in primary colon tumors; 46,8% (22/47) in 
gastric microsatellite-instable primary tumors. No 
mutations were observed in the matching healthy 
intestinal mucosa. 
All the mutations observed were insertions or 
deletions in an A8 microsatellite tract located in 
exon 28. The most frequent mutation is the deletion 
of one A (MYO1AA7MUT). All the mutations found 
appeared to be heterozygous as the wild type allele 
was also visible in all cases (figure 6, panel A). The 
MYO1AA7MUT mutation causes sub-cellular 
mislocalization (figure 6, panel B) and decreased 
stability of Myosin-1a (Mazzolini et al., 2012; 
Mazzolini et al., 2013). Additional mutations have 
been found in colorectal tumors without 
microsatellite instability (TCGA; figure 6, panel C). 
 
Table 1. MYO1A mutations related to sensorineural bilateral hearing loss (Donaudy et al., 2003). 
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Figure 6. Somatic mutations of MYO1AA7MUT. (A) Frameshift mutations in the A8 track in Exon 28 of MYO1A. (B) Co-
transfection of wild type EGFP-MYO1Awt and mutant ERFP-MYO1AA7MUT demonstrated that the mutant protein mislocalized 
to the cytoplasm of undifferentiated Caco2 cells (modified from Mazzolini et al., 2012). (C) Localization of additional mutations 
found in colorectal tumors without microsatellite instability. 
 
Implicated in 
Colorectal cancer 
Note 
The brush border protein Myosin Ia (MYO1A) has 
been demonstrated to be important for polarization 
and differentiation of colon cancer cells and is 
frequently inactivated in colorectal tumors by 
genetic and epigenetic mechanisms. Mazzolini et al. 
reported MYO1A frame-shift mutations in 32% (37 
of 116) of the colorectal tumors with microsatellite 
instability. Evidence of promoter methylation was 
observed in a significant proportion of colon cancer 
cell lines and primary colorectal tumors.  
The loss of polarization/differentiation resulting 
from MYO1A inactivation is associated with higher 
tumor growth in soft agar and in a xenograft model. 
In addition, the progression of genetically and 
carcinogen initiated intestinal tumors was 
significantly accelerated in Myo1a knockout mice 
compared with Myo1a wild-type animals. 
Moreover, MYO1A tumor expression was found to 
be an independent prognostic factor for colorectal 
cancer patients. Patients with low MYO1A tumor 
protein levels had significantly shorter disease-free 
and overall survival compared with patients with 
high MYO1A (logrank test P = 0.004 and P = 
0.009, respectively).  
The median time-to-disease recurrence in patients 
with low MYO1A was 1 y, compared with >9 y in 
the group of patients with high MYO1A. These 
results identified MYO1A as a tumor-suppressor 
gene in colorectal cancer and demonstrate that the 
loss of structural brush border proteins involved in 
cell polarity are important for tumor development 
(Mazzolini et al., 2012). 
Gastric cancer 
Note 
Frame-shift somatic mutations have been reported 
in 46,8% (22/47) of gastric microsatellite-instable 
primary tumors. Frequent MYO1A promoter 
hypermethylation was also found in gastric tumors 
(Mazzolini et al., 2013). 
Endometrial cancer 
Note 
Rare mutations have been reported in 6,2% (3/48) 
of endometrial microsatellite-instable primary 
tumors (Mazzolini et al., 2013). The low frequency 
of this mutation in endometrial tumor is likely to 
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reflect the background mutation rate occurring in 
endometrial MSI tumors. 
Nonsyndromic hearing loss 
Note 
MYO1A, which is located within the DFNA48 
locus, was the first myosin I family member found 
to be involved in causing deafness and may be a 
major contributor to autosomal dominant-hearing 
loss. Several mutations in the MYO1A gene were 
found to be associated with hearing loss (table 1) 
(Donaudy et al., 2003). In particular, the 
substitution E385D has been characterized to 
disrupt the mechanochemical coupling and 
subcellular targeting of Myosin-1a (Yengo et al., 
2008). 
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